Source comparison
Tesamorelin Dosing Protocols: Research vs Clinical Standards
Research-grade tesamorelin protocols typically follow growth hormone-releasing hormone (GHRH) dosing patterns established in clinical trials for HIV-associated lipodystrophy. The FDA-approved clinical dose for tesamorelin (brand name Egrifta) is 2mg subcutaneo
This comparison does not assign a generated winner or score.
- Research-grade tesamorelin protocols typically follow growth hormone-releasing hormone (GHRH) dosing patterns established in clinical trials for HIV-associated lipodystrophy. The FDA-approved clinical dose for tesamorelin (brand name Egrifta) is 2mg subcutaneously once daily, administered as a single injection. Research applications exploring cognitive enhancement, body composition optimisation, or metabolic function often use lower doses. 0.5mg to 1mg daily. To minimise side effects while retaining partial efficacy on growth hormone secretion.
- Tesamorelin works by binding to GHRH receptors in the anterior pituitary gland, stimulating the release of endogenous growth hormone in a pulsatile pattern that mimics natural secretion. Unlike exogenous growth hormone, which suppresses natural production, tesamorelin preserves the body's feedback loop. Growth hormone levels rise during the hours following injection, then return to baseline, allowing normal pituitary function to continue. This mechanism makes dosing frequency critical: daily administration is required because tesamorelin has a half-life of approximately 26–38 minutes in plasma, meaning it's cleared rapidly and does not accumulate.
- Clinical trials published in The Lancet and the Journal of Clinical Endocrinology & Metabolism used 2mg daily for 26–52 weeks and documented statistically significant reductions in visceral adipose tissue (VAT). The deep abdominal fat associated with metabolic syndrome. Without affecting subcutaneous fat or lean mass. Lower doses (0.5mg–1mg daily) are common in research contexts exploring neuroprotective effects or off-label metabolic applications, but published efficacy data at those levels is limited. Here's the honest answer: if your protocol calls for 0.5mg daily and you're using a 2mg vial reconstituted to 1mg/mL, you're drawing 0.5mL per dose. That vial yields exactly four doses, not the 30 doses you'd get at a 0.067mg daily dose (which isn't a standard protocol).